Fisher Asset Management LLC Lowers Stock Position in Takeda Pharmaceutical Co. $TAK

Fisher Asset Management LLC lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 59.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,484 shares of the company’s stock after selling 58,151 shares during the quarter. Fisher Asset Management LLC’s holdings in Takeda Pharmaceutical were worth $593,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. Goldman Sachs Group Inc. boosted its stake in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Brandes Investment Partners LP increased its stake in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after purchasing an additional 208,136 shares in the last quarter. Managed Asset Portfolios LLC raised its holdings in Takeda Pharmaceutical by 1.3% in the 2nd quarter. Managed Asset Portfolios LLC now owns 1,488,843 shares of the company’s stock worth $23,018,000 after purchasing an additional 19,177 shares during the period. Bank of America Corp DE raised its holdings in Takeda Pharmaceutical by 225.8% in the 2nd quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after purchasing an additional 718,805 shares during the period. Finally, Quantinno Capital Management LP boosted its position in Takeda Pharmaceutical by 54.5% during the second quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock worth $12,322,000 after purchasing an additional 280,992 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on TAK. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

TAK opened at $17.87 on Friday. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.82. The firm has a market capitalization of $56.87 billion, a PE ratio of 74.46 and a beta of 0.01. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average price is $17.20 and its 200 day moving average price is $15.46.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The company had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $7.81 billion. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.